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Abstract
Background:  Follicle stimulating hormone (FSH) has been routinely used for ovulation induction.
Because of rapid clearance of the hormone, FSH is commonly administered by daily intramuscular or
subcutaneous injections in in-vitro fertilization (IVF). To reduce the number of visits to the clinic, an
intermittent vaginal injection of rhFSH every 3 days employing the concepts of mesotherapy and uterine
first-pass effect was invented and has successfully been applied in women receiving IVF treatment. This
study was designed to monitor the pharmacokinetic pattern of rhFSH administered vaginally.
Methods: Twelve healthy women with regular ovulatory cycles were recruited. All volunteers received
gonadotrophin-releasing hormone agonist to suppress pituitary function and were assigned to receive
single dose recombinant human FSH (rhFSH, Puregon 300) either using conventional abdominal
subcutaneous injection or vaginal subcutaneous injection in a randomized cross-over study. Serum samples
were collected at pre- scheduled time intervals after injections of rhFSH to determine immunoreactive
FSH levels. Pharmacokinetic parameters characterizing rate [maximal plasma concentrations (Cmax) and
time of maximal plasma concentrations (tmax)] and extent [area under the plasma concentration-time
curve (AUC) and clearance] of absorption of rhFSH were compared.
Results: Vaginal injection of rhFSH was well tolerated and no drug-related adverse reaction was noted.
Our analysis revealed that tmax was significantly earlier (mean 6.67 versus 13.33 hours) and Cmax was
significantly higher (mean 17.77 versus 13.96 IU/L) in vaginal versus abdominal injections. The AUC0-∞ was
1640 versus 1134 IU·hour/L in vaginal and abdominal injections, respectively. Smaller plasma elimination
rate constant (0.011 versus 0.016 hour-1), longer mean residence time (106.58 versus 70.47 hours), and
slower total body clearance (292.2 versus 400.1 mL/hour) were also found in vaginal injection.
Conclusion: The vaginal injection mode elicited a rapid and highly extended absorption of rhFSH injected
compared to conventional abdominal injection. These data indicate that the rate and extent of FSH
absorption from the injection site can vary depending on the route of the FSH administration.
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Background
Follicle stimulating hormone (FSH) has been widely
employed for ovulation induction and in-vitro fertiliza-
tion. The ability of FSH to promote folliculogenesis is
dependent on the plasma level of FSH that develops after
administration [1-3]. The relatively short elimination
half-life and rapid metabolic clearance of current FSH
preparations requires that daily injections are adminis-
tered to maintain steady state FSH levels above the thresh-
old level during ovarian stimulation [4]. The invention of
recombinant human FSH (rhFSH) preparations, devoid
of other gonadotrophins or inactive contaminants, made
self-subcutaneous-injection possible [5]: commonly, the
patient's spouse or another non-professional individual
will perform the injections. However, in under-developed
and developing countries or areas such as in Taiwan and
China, many women still travel every day to receive gona-
dotrophin injections at the IVF clinic [6].
To reduce the number of visits to the clinic, an alternative
treatment regime of vaginal injections of rhFSH every 3
days [7] employing the concepts of mesotherapy [8] and
uterine first-pass effect [9,10] has been developed. Meso-
therapy [11], the injection of minimal amounts of medi-
cines into the hypodermis and dermal layer at weekly
intervals, can achieve the same pharmacological effects as
daily intramuscular injections. The basic premise of mes-
otherapy was: smallest dose, infrequently, in the correct
location [8]. A countercurrent exchange with vein-to-
artery diffusion between upper vagina and uterus has
been shown to result in the uterine first-pass effect [9,10].
This fact has been applied in the vaginal administration of
progesterone supplements, with much higher progester-
one delivery to the uterus when compared with intramus-
cular injections [12]. The existence of the uterine-ovarian
countercurrent system has also been proven [13].
Intermittent vaginal injection of rhFSH has successfully
been applied in women receiving IVF treatment [14]. The
present study was a follow up of our previous works and
designed to monitor the pharmacokinetic pattern of
rhFSH administered vaginally versus abdominally and to
investigate whether plasma level of FSH differs depending
on the route of the hormone administration.
Methods
Study population
Twelve healthy women with regular ovulatory cycles were
recruited. They were in good cooperative condition and
had not been exposed to oral pills or other forms of hor-
mone therapy for at least 3 months preceding the study.
All volunteers were nonsmokers, ovulatory (with a mean
cycle length of 26-32 days and intra-subject variation of ±
2 days), and without evidence of ovarian disease. The
uterine cervix Pap smears for all volunteers were normal.
Women with evidence of polycystic ovarian syndrome or
ultrasound evidence of ovarian cysts were excluded from
the study. All subjects were also devoid of any medical dis-
orders such as hypertension, hepatic or renal diseases, and
endocrine abnormalities. All subjects signed the informed
consent to the study protocol, which had been approved
by the Ethical Committee of the institution. The study was
conducted in agreement with the Declaration of Helsinki
for Medical Research Involving Human Subjects.
Study design
This was a randomized, single-center, two-period cross-
over study, with each subject undergoing two trial cycles
using alternative injection sites. The site for the first cycle
of injection was randomized to be either the abdomen or
vagina. All subjects received oral pills (Marvelon, contain-
ing 0.030 mg ethinyl oestradiol and 0.150 mg desogestrel,
NV Organon, Oss, The Netherlands), starting at day 3 of
the precedent cycle. A gonadotrophin-releasing hormone
(GnRH)-agonist nasal spray (Buserelin acetate, Aventis
Pharma Deutschland GMBH, Frankfurt, Germany) was
given daily from day 18 of that cycle to achieve proper
pituitary down-regulation of GnRH followed ovarian
hyperstimulation [14] and GnRH-agonist was maintained
throughout ovarian hyperstimulation to the last day of
the monitoring in each mode of injection. On the morn-
ing of period day 3, the study subjects visited the clinic
where a 20-gauge intravenous catheter with a heparin lock
was placed at forearm and levels of baseline plasma hor-
mones including FSH, estradiol (E2) and lutenizing hor-
mone (LH) were monitored. A vaginal ultrasonographic
scan was performed to check for the absence of ovarian
cyst or any ovarian pathology. The subjects then received
rhFSH injections in one of two injection modes once pitu-
itary suppression was achieved as manifest by serum E2 <
50 pg/mL, LH < 2.5 mIU/mL, and FSH < 10 mIU/mL. All
subjects received a single dose of Puregon solution for
injection in cartridges [rhFSH, Puregon 300, Organon
(Ireland) Ltd. Swords, Co. Dublin, Ireland]. The formula-
tion was a ready-for-use solution containing 833 IU/mL
in-vivo bioactivity of FSH.
For vaginal injections, the subjects were placed in Trende-
lenburg's position after ultrasonographic scanning. A ster-
ilized speculum was inserted and vaginal discharge
thoroughly cleaned with sterilized normal saline and Pov-
idone iodine solution. The rhFSH (one vial of Puregon
300, ~425 IU rhFSH in 0.525 mL) was aspirated into a 1
mL syringe fitted with a 30 gauge × 1/2 inch (0.31 × 13
mm) needle. To mimic the serum concentrations of
rhFSH administered in clinical IVF protocol, the injection
was performed as that used in ovarian hyperstimulation
[14] with the needle angled at 15-30° towards the vaginal
mucosa and inserted at the middle to upper portions of
bilateral vaginal wall at positions corresponding approxi-Reproductive Biology and Endocrinology 2009, 7:107 http://www.rbej.com/content/7/1/107
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mately to 3 o'clock and 9 o'clock. The rhFSH was injected
at a depth of 1-2 mm into the vaginal wall. For abdominal
injections, rhFSH solution was injected with a 26 gauge ×
1/2 inch (0.45 × 13 mm) needle subcutaneously at a
depth of 13 mm under the skin of anterior abdominal
wall at the level of the umbilicus 5-10 cm from the mid-
line.
The procedure was repeated in a two-way random
sequence, cross-over fashion: once a cycle with one mode
of injection was completed, for volunteers' convenience,
the subjects were monitored for 2-6 months before the
second cycle with the alternate mode of injection was car-
ried out. The time frame of 2-6 months provides a suffi-
cient washout to prevent the carry-over effects and this
also fits well with clinical practice that a successive IVF
cycle to be carried out. After vaginal rhFSH injections, the
subjects were asked to keep abstinence for at least one
week to avoid the interference of vaginal blood flow alter-
ations during intercourse. Subjects were allowed to
resume their normal activities after the injection.
Assessment
In addition to baseline samples, peripheral blood samples
were taken at time intervals after the injections as below:
0.5 (optional), 1, 2, 4, 6, 8, 10, 12, 14 (optional), 24, 48,
72, 96, 120 hours, and optionally 144, 168, 192, 216,
240, 288, 312, 336, 360 hours. Exudates from the injec-
tion points in the vaginal cavity immediately after vaginal
injections were collected. Serum samples and supernatant
of vaginal exudates were frozen at - 20°C until assess-
ment. All hormones were measured using commercially
available kits (Diagnostic Systems Laboratories, Inc. Web-
ster, Texas, USA). Estradiol concentrations were measured
by a competitive radioimmunoassay (Ultra-sensitive
estradiol RIA DSL-4800). The sensitivity of the assays was
2.2 pg/mL and the inter-assay coefficient of variation (CV)
was 8.0%. Follicle-stimulating hormone and LH concen-
trations were measured by a two-site immunoradiometric
assay (FSH IRMA DSL-4700, LH IRMA DSL-4600) with
two monoclonal antibodies. Data are expressed in terms
of IRP 78/549 and 68/40 for FSH and LH, respectively.
The sensitivity of the assays was 0.11 mIU/mL and 0.12
mIU/mL and the inter-assay CV was 6.2% and 7.0%,
respectively for FSH and LH. Follicle growth was followed
up at 72 hours and 120 hours after injections.
Pharmacokinetic analysis
The data from the plasma concentration versus time curve
were evaluated to derive the following pharmacokinetic
parameters: measured maximal plasma concentration
(Cmax); time to reach measured maximal plasma concen-
tration (tmax); plasma elimination rate constant (Kel),
determined from simple linear regression based on the
terminal log-linear part of the last quantifiable plasma
concentration versus time profile; apparent half-life (t1/2),
the half life determined with the terminal phase of the last
quantifiable plasma concentration-time profile, calcu-
lated as t1/2 = (0.693)/Kel; summation of area under the
plasma concentration-time curve from time zero to the
time of last quantifiable concentration by the linear trap-
ezoidal rule (AUC0-t); summation of area under the
plasma concentration-time curve from time zero to the
time of last quantifiable concentration (AUC0-∞), calcu-
lated by the linear trapezoidal rule, and extrapolated to
infinity estimated by the last quantifiable concentration
divided by Kel; mean residence time (MRT); square of the
correlation coefficient between the observed and mod-
elled data values (RSQ), indicates the proportion of varia-
bility in a data set that is accounted for by a statistical
model;volume of distribution based on the terminal
phase (Vz); and total body clearance (CL = Dose/AUC).
All pharmacokinetic parameters were calculated using
non-compartment methods with the computer program
WinNonlin™, version 5.2 (Scientific Consulting Inc.,
Apex, NC, USA). In this instance, the endogenous serum
FSH concentration (baseline concentration) was sub-
tracted from all after dosing serum FSH concentration,
thereby, assuming a constant endogenous serum FSH over
the study interval [15].
Statistical analysis
The comparison of the rate of absorption for the two
injection modes was tested using Cmax, and tmax, while the
extent of absorption was tested using AUC0-∞, AUC0-t, and
CL. The conventional abdominal injection was taken as
reference formulation and the vaginal injection as test
treatment. All pharmacokinetic parameters were calcu-
lated at 95% confidence intervals. Comparison of phar-
macokinetic parameters, between the phases of
administration, was performed using paired tests (Min-
itab software, version 14). A one-way analysis of variance
(ANOVA) was performed for the comparison of mean val-
ues of pharmacokinetic parameters between two injection
modes. We also used MANOVA (SPSS, version 12.0) for
repeated measures to ascertain differences (within-sub-
jects and between-subjects effects) with respect to the
changes of FSH concentration in the time sequence of this
trial. A post hoc multiple comparisons on both injection
modes was performed using Dunnett (2-sided) t test.
Data are presented as mean ± SD unless stated otherwise.
Differences were considered to be statistically significant if
P < 0.05. As this administration method was a new inven-
tion and there was no previous information regarding the
rate and extent of FSH absorption employing this injec-
tion method, we did not carry out the power analysis a
priori. For number of volunteers (12 cases) recruited, we
followed the pioneer works on the pharmacokinetics of
recombinant human FSH (15).Reproductive Biology and Endocrinology 2009, 7:107 http://www.rbej.com/content/7/1/107
Page 4 of 10
(page number not for citation purposes)
Safety parameters
The injection sites were monitored at 1, 24 and 72 hours
post injection for redness, itching, swelling, pain and
bruising with the scoring as none, mild, moderate or
severe. Any abnormal discharge or lesions during pelvic
examination or vaginal injection was reported.
Ethical Consideration
Informed consent was given. All subjects were told exactly
why this study was taking place and the potential benefits
from the study, and then invited to take part without any
pressure being put on them to do so. Subjects were
allowed to withdraw freely at any time, and if they did,
their contribution to the study removed. The researcher
did as much as possible to protect subjects from any harm
resulting from their participation in this study, and to
minimize disturbances to the subjects. The records of
individual subjects were kept confidential and any infor-
mation that will be published from the study will not
identify the result of specific individuals.
Results
The mean age of the twelve subjects was 31.2 ± 7.3 (range
20-43) years with mean body weights of 46.1 ± 3.4 (range
39.4-50) kg, mean body height of 156 ± 5 (range 150-
165) cm, and mean body mass index of 19.4 ± 2.1 (range
17.3-24.4) kg/m2. All subjects completed two cycles of
rhFSH injections. Immediately before administration of
rhFSH, the mean plasma FSH concentration was 5.16 ±
2.16 IU/L versus 5.45 ± 2.32 IU/L and the mean plasma E2
concentration was 25.4 ± 20.9 pg/mL versus 25.3 ± 17.0
pg/mL for abdominal and vaginal injections, respectively.
After rhFSH injections, blood samples were taken as
scheduled up to 120 hours in all subjects. In six subjects
receiving vaginal injections and two receiving abdominal
injections, further blood samples were taken up to 360
hours after injection. In vaginal injections, 0.5-3 mL of
bloody exudates was aspirated immediately after injec-
tions. The volumes of exudates were relatively consistent
among injections with median value of 0.7 mL and only
one case had exudates over 1 mL. The mean FSH concen-
tration in the exudates was 30.75 ± 7.54 IU/L. Thus, of the
amount of rhFSH was lost during the injection procedure
was only small portion of rhFSH (425 IU) injected. No
exudates were noted after abdominal injections.
Local tolerance
Local reactions were all mild and generally short-lived in
both administration modes. After abdominal injections,
redness, swelling and pain were reported in one subject at
1 hour but none at 24 and 72 hours. Bruising occurred in
two subjects at 1 hour and persisted at 24 and 72 hours.
After vaginal injections, no redness or swelling was found
at 1 and 24 hours. Pain was experienced by two subjects
during vaginal injection but none at 1 and 24 hours.
Bruising occurred in three subjects at 1 hour and in two
subjects persisted until 24 and 72 hours. No subjects expe-
rienced an itching sensation in either injection modes.
Pharmacokinetic analysis
The mean data of plasma FSH at different time intervals
are shown in Figure 1. There is moderate to high inter-
individual variability; the mean CV for vaginal injection is
32% and for abdominal injection is 27% for raw data cal-
culated up to 120 hours. In general, the plasma FSH levels
could be divided into 3 phases: 0-24 hours, 24-72 hours,
and 72-360 hours, with higher elevated FSH concentra-
tions in 0-24 hours in women receiving vaginal injections
compared to those in women receiving abdominal injec-
tions, while in the 24-72 hours period a similar curve of
FSH levels were produced in both groups with higher FSH
concentrations in women receiving abdominal injections
(Figure 1 and figure 2). The FSH concentrations remained
at a low level (< 3 IU/L) at the time between 72 and 360
hours in those receiving abdominal rhFSH injections, but
it remained on higher concentrations (> 5 IU/L) during
this time-frame in those receiving vaginal rhFSH injec-
tions (Figure 1).
Only data up to 120 hours were analyzed for pharmacok-
inetic parameters, as not all subjects were monitored after
this time point. Individual pharmacokinetic parameters
are presented in Tables 1 & 2 (See Additional files 1 &2).
The mean values of the pharmacokinetic parameters
obtained are presented in Table 3 (See Additional file 3).
After single dose of 425 IU rhFSH, peak plasma FSH con-
centrations occurred significantly earlier (tmax 6.67 versus
Plasma FSH concentrations after abdominal or vaginal subcu- taneous injections of 425 IU recombinant human FSH in  twelve women under pituitary down-regulation with GnRH- agonist Figure 1
Plasma FSH concentrations after abdominal or vagi-
nal subcutaneous injections of 425 IU recombinant 
human FSH in twelve women under pituitary down-
regulation with GnRH-agonist. Mean FSH concentra-
tions versus time points were presented. The vaginal injec-
tion mode elicited a rapid and higher extended absorption of 
FSH injected.Reproductive Biology and Endocrinology 2009, 7:107 http://www.rbej.com/content/7/1/107
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13.33 hours; P < 0.05) and were higher (Cmax 17.77 versus
13.96 IU/L; P < 0.05) in vaginal versus abdominal injec-
tions. There was also increased net absorption (AUC0-∞
1640 versus 1134 IU·hours/L; P < 0.05) in vaginal versus
abdominal injection. However the net absorption up
until the last quantifiable concentration (AUC0-t) showed
no difference in both groups. The apparent half-life, t1/2,
was about 1.5 times longer (66 versus 46 hours; P < 0.01)
in those receiving vaginal injections and this was closely
associated with a significant smaller plasma elimination
rate constant, Kel (0.011 versus 0.016 hour-1; P < 0.005),
longer mean residence time (106.58 versus 70.47 hours; P
< 0.001), and a much slower total body clearance, CL
(292.2 versus 400.1 mL/hour; P = 0.005) compared to
those of abdominal injection. There was no difference in
the volume of distribution in both modes of administra-
tion.
MANOVA for repeated measures showed significant dif-
ference of serum FSH levels in relevant to the time effect
for both abdominal and vaginal injection modes (Table 4,
See Additional file 4). The tests of within-subjects effects
and between-subjects effects were remarkable (P < 0.01).
The post hoc analysis indicated that the serum FSH con-
centrations showed significant difference from baseline
level at 1 to 24 hours after rhFSH administration in the
vaginal injection group while in the abdominal injection
group the significant different values were from 1 to 48
hours after rhFSH administration (Table 5 & 6, See Addi-
tional files 5 &6).
The LH level was sustained in profoundly suppressed val-
ues (< 2.0 IU/L) monitored up to 360 hours after rhFSH
injections in both groups. The E2 level was elevated 24-96
hours after injections in both groups with higher levels
Plasma concentration-time profile of each individual and mean increases of immunoreactive FSH after abdominal and vaginal  subcutaneous injections of 425 IU recombinant human FSH in twelve women under pituitary down-regulation with GnRH-ago- nist Figure 2
Plasma concentration-time profile of each individual and mean increases of immunoreactive FSH after 
abdominal and vaginal subcutaneous injections of 425 IU recombinant human FSH in twelve women under 
pituitary down-regulation with GnRH-agonist. Compared to baseline FSH level, significant differences were noted at 1 
to 24 hours of vaginal injections and at 1 to 48 hours of abdominal injections (Table 5 & 6, See Additional files 5 &6).Reproductive Biology and Endocrinology 2009, 7:107 http://www.rbej.com/content/7/1/107
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noted in the abdominal injections (Figure 3). The peak
level of E2 was 202 and 89 pg/mL at 48 hours in abdom-
inal and vaginal injections, respectively. Following
abdominal injections, the E2 concentrations dropped
sharply to below 10 pg/mL after 120 hours and remained
at very low level up to 360 hours. The E2 levels in those
who received vaginal injections were maintained at above
30 pg/mL after 120 hours with a second peak concentra-
tion of 112 pg/mL at 240 hours and then dropped sharply
to below 10 pg/mL. This pattern of E2 levels correlated
with FSH concentrations which plateau after 72 hours
with a second peak at 240 hours in the vaginal injection
group (see Figure 1). No follicle larger than 13 mm was
detectable at 72 hours and 120 hours after injections in
both injection modes.
Discussion
The present study defines the pharmacokinetics of rhFSH
administered vaginally compared with conventional
abdominal SC injection. The vaginal injection mode elic-
ited a rapid and highly extended absorption of rhFSH
injected compared to conventional abdominal injection.
The enhanced absorption was indicated by a shorter time
to peak plasma concentrations with higher maximal
plasma concentrations, while extended absorption was
manifest by higher area under the plasma concentration-
time graph (AUC0-∞), lower elimination rate constant,
and slower total body clearance. The data we obtained
indicate that the rate and extent of FSH absorption from
the injection site can vary depending on routes and meth-
ods of FSH administration. We have also demonstrated
that vaginal SC administration of rhFSH had no adverse
impact on women receiving the injection.
One of the main findings of this study is that the absorp-
tion of rhFSH injected vaginally (manifest as higher Cmax
17.77 IU/L with shorter tmax 6.67 hour) was more rapid
than conventional abdominal SC injections. Different
pharmacokinetic data were found in studies in pituitary
down-regulated normal women with Cmax of 3 to 6.9 IU/
L, tmax of 16-17 hours in SC single dose injections of 300
IU rhFSH [15-18]. High intra-individual variability and
broad absorption peaks for rhFSH have been indicated to
account for variations noted in the tmax [19]. The reagents
used in the pituitary down-regulation can be used to
explain the variations of Cmax. The baseline FSH was sup-
pressed to below 0.25 IU/L in cases that received high
dose oral pills [19] or received GnRH-agonist depot prep-
arations [15-17] versus below 10 IU/L in those received
GnRH-agonist nasal spray [20].
The increased absorption of rhFSH is another prominent
feature of the vaginal injection. Compared to previous
similar studies using a single 300 IU rhFSH injection, the
extent of absorption revealed by the AUC0-∞ in the present
study (1134 and 1640 IU·hours/L in abdominal and vag-
inal SC injections, respectively) is much higher than that
of 339 IU·hours/L in IM injection [21], of 456 IU·hours/
L in SC injection [18], and of 598 IU·hours/L in IV injec-
tion [15]. The higher AUC0-∞ in vaginal injection may lead
to the impression of higher bioavailability of rhFSH
administered in this mode. However, very similar relative
bioavailability of 1.127 and 1.068, calculated using the
formula of CL·AUC/Dose [22] were found in vaginal and
abdominal injections, respectively. Thus, the correct dose
(425 IU in this study) of rhFSH was injected in both
modes to achieve a therapeutic systemic exposure. A more
comparable pattern of AUC0-t  in this study further
reflected similar relative bioavailability of both injection
modes. The total clearance of 0.40 and 0.29 L/hour in
abdominal and vaginal SC injections, respectively in this
study is much slower than a previous study of 0.5-0.6 L/
hour in IV injection of 300 IU of rhFSH [15] and of 0.75
L/hour in SC injection of 150 IU of rhFSH [19]. The vol-
ume of distribution was around 3 L in both groups, indi-
cating that the rhFSH was generally distributed in plasma.
The elimination rate constants in the present study (0.016
versus 0.011 hours-1 in vaginal versus abdominal injec-
tions) are also much lower than that of 0.03 hours-1 in
both SC and IM injections of HMG [20]. The mean resi-
dence time of 107 hours in vaginal injection versus 70
hours in abdominal injection is well correlated with
longer apparent plasma half-life.
Though the endogenous FSH was not fully suppressed in
the present study, the estimation of elimination half-life
Serum E2 concentrations after vaginal or abdominal subcuta- neous injections of 425 IU recombinant human FSH in  women under pituitary down-regulation with GnRH-agonist Figure 3
Serum E2 concentrations after vaginal or abdominal 
subcutaneous injections of 425 IU recombinant 
human FSH in women under pituitary down-regula-
tion with GnRH-agonist. Mean concentrations of E2 ver-
sus time points were presented. An initial higher E2 levels 
were noted in those of abdominal injections but a more con-
sistent elevated E2 was found in those of vaginal injections.Reproductive Biology and Endocrinology 2009, 7:107 http://www.rbej.com/content/7/1/107
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of 46 hours in abdominal SC injection of the present
study is similar to that of 37 hours in SC/IM [16,17], and
44 hours in IM [21] single 300 IU rhFSH injections. How-
ever, the estimation of apparent plasma half-life (66
hours) for vaginal injection in the present study is about
1.5 times of that for abdominal injection. We recognize
that there may present minimal endogenous FSH secre-
tion in this study. The elimination half-life of FSH
obtained from cases received abdominal SC injections
was very similar to those of previous studies employing
fully suppressed pituitary endogenous FSH secretion.
Thus, the lower level fluctuation of baseline endogenous
FSH secretion may not affect the result of pharmacoki-
netic analysis in the present study. As this is a cross-over
study, volunteers received both abdominal and vaginal
injections, FSH concentrations in the vaginal injection
group are thus comparable to those of abdominal injec-
tion. A similar pattern of prolonged elimination half-life
could only be found in studies using long-acting FSH
preparations with either a C-terminal modified form of
FSH resulting in slow absorption [23,24] or the glycosyla-
tion of an N-terminal extension to prolong the half-life of
FSH [25]. Chemical alterations of FSH, such as the
removal of sugars from the carbohydrate side chains or
nicks in the peptide chains, at injection sites before
absorption into general circulation, has been noted to
affect the mean residence time and the rate of clearance
[20]. The possibility that vaginal injection may lead to
alteration of peptide chains of rhFSH at injection sites or
affect the galactose-terminal complex of rhFSH and its
clearance rate and plasma half-life needs to be investi-
gated further.
Studies have shown that some drugs administered vagi-
nally may provide rapid and complete systemic absorp-
tion and much higher levels of both E2 and estrone were
found following the vaginal dose compared to the oral
dose [26]. The development of vaginal progesterone
administration for luteal support [10,12] showed that
lipid soluble steroid hormones are rapidly absorbed in the
vagina, achieve quick local effects to the uterus, and avoid
the first pass hepatic metabolic effect [12]. With an inject-
able recombinant protein such as rhFSH, though there is
no identifiable mechanism to suggest that vaginal admin-
istration would be superior as is seen with steroid hor-
mones vaginal administration, the clinical effectiveness of
vaginal administration of rhFSH has been proved in our
previous study [14]. Employing the concept of uterine
first-pass effect and the uterine-ovarian countercurrent
system, the medicines were injected into bilateral vaginal
walls in our study to allow rhFSH to be transported to
bilateral ovaries in a shortest distance. The injection depth
we used in this study was 1-2 mm (as commonly used in
the mesotherapy) into vaginal mucosa, in the areas of
lamina propria and tunica propria, the connective tissue
layers containing extensive vascular channels and elastic
tissue [27]. A portion of rhFSH injected vaginally might
have absorbed and transported more efficiently to the sys-
temic circulation through the extensive vascular channels
in these area of the vagina. This mechanism may explain
the more rapid absorption of vaginal SC injection com-
pared to abdominal SC injection. We did not have data for
a single site vaginal injection, nor did we have data for two
injection sites in abdominal injections. Further studies are
required to clarify this issue. As far as the sexual inter-
course after the vaginal injections of rhFSH might affect
the distribution of medicines injected and the pharma-
cokinetic patterns, volunteers receiving vaginal injections
were advised to abstain for at least one week. In the clini-
cal practice of IVF treatment, the couples were commonly
discouraged to have intercourse for at least 3-5 days after
embryo transfer. In the present study, we do not have any
data or information to support the observed pharmacoki-
netics in relevant to the coital activity in the peri-ovulatory
period.
The concept of mesotherapy may explain why medicines
persist for longer when injected into superficial subcuta-
neous and/or dermal layers, as was used for the vaginal
injections in this study. Studies have suggested that the
skin is a natural time-release system, with medicine
injected into superficial subcutaneous and/or dermal lay-
ers remains in the injected area longer as it is cleared more
slowly by the general circulation than medicine injected
more deeply [28,29]. The anatomic characteristics of the
dermal layer, with oriented tropocollagen polypeptide
macromolecules and subdermal tissues merging with the
fat-containing subcutaneous tissue, contribute to this
effect: the skin epithelium acts as the reservoir and medi-
cine injected into these layers may be temporarily reserved
locally [30]. The vaginal epithelium and lamina propria/
tunica propria might also serve as a reservoir, with medi-
cines administered here kept within this local area and
released or absorbed slowly into blood circulation.
Besides the rapid absorption as described above, another
characteristic of the vaginal injection mode observed in
this study is the extended and prolonged smoother tem-
poral profile of plasma FSH levels. This modulated tem-
poral profile is likely to produce more sustained and less
fluctuating plasma FSH levels during rhFSH administra-
tion. Thus, the rhFSH administered vaginally employing
mesotherapy presented with two phases of absorption: a
fast phase indicated by the higher Cmax with shorter tmax,
and a second phase with extend absorption reflected by
the higher AUC0-∞, and slower total body clearance. The
clinical significance of higher and more stable FSH levels
for ovulation induction and IVF treatment, however,
remains to be determined.
As the present study employed a single dose injection of
rhFSH, the serum FSH level elaborated may not sustain
enough to override the window of threshold for properReproductive Biology and Endocrinology 2009, 7:107 http://www.rbej.com/content/7/1/107
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follicular growth and there were only transiently elevated
levels of E2 detected in both groups. The serum FSH
threshold for follicular growth has been found stably at
approximately 7.8 IU/L in women with regular menstrual
cycles [31]. Higher E2 level found in those receiving
abdominal injections in this study may reflect the slightly
higher serum FSH concentration (over the FSH threshold
of 7.8 IU/L) up to 48 hours (Figure 2 and Table 5 & 6, See
Additional files 5 &6). On the contrary, serum FSH con-
centration in those of vaginal injection to surpass the FSH
threshold was found only up to 24 hours (Figure 2 and
Table 5 & 6, See Additional files 5 &6). In fact at 48 hours
after rhFSH injections, 10 out of 12 cases in abdominal
injection group surpassed the FSH threshold while only 3
out of 12 cases in vaginal injection group had serum FSH
concentration over the FSH threshold of 7.8 IU/L (Figure
4). This fact might explain a higher E2 level found around
48-72 hours in those of abdominal injections even
though in general the rhFSH absorption was higher in
those of vaginal injections. The level of E2 dropped
sharply to baseline level after 96 hours reflects the serum
concentrations of FSH may not have maintained for follic-
ular growth. In contrast, E2 levels in those who received
vaginal injections were maintained at above baseline level
after 120 hours with a second peak at 240 hours and then
dropped sharply to below baseline level thereafter. This
pattern of E2 levels was well correlated with plateau con-
centrations of FSH in those who received vaginal injec-
tions. As this study represents only limited numbers of
cases, the disparity of estradiol and FSH levels in the dif-
ferent administration modes, however, needs further
investigation. Though follicle growth was not completely
examined in the present study, our previous works
showed proper folliculogenesis with mature oocyte num-
bers, fertilization rates, and pregnancy rates were achieved
in the intermittent vaginal administration of rhFSH in IVF
treatment [14]. The doses of rhFSH needed for ovulation
stimulation in clinical IVF treatment were half of those
used for conventional SC injection method [14]. Thus,
intermittent vaginal injection may provide an alternative
treatment regime, avoiding excessive use of gonado-
trophins for controlled ovulation stimulation which may
lower the clinical pregnancy and live birth rates [32].
There is a trend of reducing injections of gonadotropins in
the last decade. The main advantages of less frequent dos-
ing are an increase in patient convenience, fewer chances
for mistakes during drug administration and improved
compliance [33]. Our present work with enhanced extent
of absorption and longer apparent plasma half-life of
rhFSH provides the pharmacokinetic basis for the inter-
mittent injections. Besides intermittent vaginal injections,
there were few studies also aimed to reduce the injections
of gonadotropins. Intermittent administration of rhFSH
(every 3 days up to day 6) followed by daily injection, has
been applied in IVF treatment and significantly reduces
the total number of injections, compared with a conven-
tional FSH regimen [34]. A loading dose of 300 IU rhFSH
followed by 3 treatment free days, and a return to daily
injections has also been successfully used for ovulation
induction in polycystic ovarian syndrome [35]. Recent
development of long acting FSH which was administered
as single dose to sustain the FSH level for 7 days followed
by daily injection of rhFSH also can achieve similar ovar-
ian stimulating effects compared with a conventional FSH
regimen [36].
Subcutaneous injection of FSH can cause some side reac-
tions, depending on variables such as medicines, needle
size and injected volume. In this study, injection of rhFSH
via both abdominal and vaginal routes was well tolerated
and local reactions were all mild and short-lived. No
apparent differences with respect to local tolerance were
observed. A detailed pre-injection counselling and
description of the new method is mandatory to reassure
the patients that the procedure is unlikely to cause signif-
icant discomfort. Generally, the method of administra-
tion by the vaginal route is more difficult than abdominal
injections and requires a health professional to accom-
plish. However, the slight burden of physician/nurses pro-
vides advantages of less frequent dosing with an increase
in patient convenience and fewer chances for mistakes
during drug administration.
There are few shortcomings in the original design of this
trial including (1) the small numbers of the subject
enrolled which might result in less significant power in
the statistical analysis; and (2) the endogenous FSH was
not fully suppressed which made it difficult to provide a
The percentage of cases with plasma FSH level higher than  the FSH threshold (> 7.8 IU/L) after abdominal or vaginal  subcutaneous injections of 425 IU recombinant human FSH  in women under pituitary down-regulation with GnRH-ago- nist Figure 4
The percentage of cases with plasma FSH level 
higher than the FSH threshold (> 7.8 IU/L) after 
abdominal or vaginal subcutaneous injections of 425 
IU recombinant human FSH in women under pitui-
tary down-regulation with GnRH-agonist.Reproductive Biology and Endocrinology 2009, 7:107 http://www.rbej.com/content/7/1/107
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reliable pharmacokinetic analysis especially in the elimi-
nation half-life. As the volunteers were generally difficult
to recruit in the cross-over study, the number of the sub-
jects used in previous similar analysis of pharmacokinet-
ics on rhFSH [15,17-20] was followed. In this two-period
cross-over trial of 12 volunteers, the mean log Cmax for
abdominal injection was 1.14 and that for vaginal injec-
tion was 1.24 and the pooled within-subject variation was
SD = 0.10. If the two-sided power is set at 80%, with the
test size 10%, then N = 6 to 8 subjects would need to be
recruited in the bioequivalence of the ratio of two means
[37,38]. This indicates that 12 cases are enough for this
study. Future study with more subjects and with fully sup-
pressed endogenous FSH may help to clarify those issues
and provide even higher power in the analysis.
Conclusion
We conclude that rhFSH administered vaginally has a
higher rate and extent of absorption. Though the data in
this study were for a single injection, the efficiency of
intermittent serial vaginal injections of rhFSH had been
analyzed in another study, which showed proper follicu-
logenesis and the in vitro fertilization rate and clinical
pregnancy rate [14]. This injection mode thus provides a
more cost-effective regimen for gonadotropin therapy.
The potential therapeutic value of higher and prolonged
FSH concentrations, as in vaginal administration, war-
rants further consideration.
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